Company Overview and News
KUALA LUMPUR (Aug 13): The FBM KLCI is seen starting the week on a flat note and struggle to defend the 1,800-point level, tracking the weaker close at most global markets last Friday.
7223 7168 7027 0082 5246 9695 5025 5014 CIMDF 1023 5754 4995 7219 MYPRY
KUALA LUMPUR (Aug 10): Based on corporate announcements and news flow today, stocks in focus on Monday may include the following: Malaysia Smelting Corp Bhd, Westports Holdings Bhd, YFG Bhd, Marine & General Bhd, NWP Holdings Bhd, Minetech Resources Bhd, Green Packet Bhd, Malaysia Airports Holdings Bhd, PRG Holdings Bhd, CIMB Group Holdings Bhd, Utusan Melayu (Malaysia) Bhd, Versatile Creative Bhd, PLS Plantations Bhd, Petrol One Resources Bhd and Jadi Imaging Holdings Bhd.
7223 7168 7027 0082 5246 9695 7099 5025 5014 CIMDF 1023 5754 4995 7219 MYPRY
KUALA LUMPUR (Aug 10): NWP Holdings Bhd said today it has decided to abort a RM744.96 million contract to construct affordable housing under six projects of SPNB Aspirasi Sdn Bhd and Perbadanan PRIMA Malaysia, due to the lack of progress made in negotiations.
BSMAF 5025 1818
KUALA LUMPUR: JF Apex Research expects IHH Healthcare Bhd , Kelington Group Bhd , NWP Holdings Bhd and Salcon Bhd to generate trading interest following their latest corporate news.
5225 FORTIS Q0F 0151 5025 IHHHF 532843
KUALA LUMPUR, March 15 — Bursa Malaysia closed at an intra-day low today on nervousness over the direction of US economic and foreign policies, leaving the local bourse in the red throughout the day, dealers said.
PBLOF 5225 Q0F 1295 BSMAF 1481 5025 IHHHF 1818
KUALA LUMPUR, March 14 — Bursa Malaysia closed lower today, echoing global and regional equity performances on rampant profit-taking, leaving the indices in the red throughout the day, dealers said.
5238 PNADF PBLOF 1295 BSMAF 5025 PNAGF 6033 0152 1818
KUALA LUMPUR, March 13 — Shares on Bursa Malaysia remained in the red at mid-morning today with traders still affected by the mixed overnight performance of Wall Street and as domestic traders offload shares from yesterday's gains.
1201 PBLOF 1295 BSMAF 5025 1818
KUALA LUMPUR, March 12 — Bursa Malaysia closed higher today on the back of continued escalating demand, with traders active throughout the day and registering positives across the board in trying to obtain bargains, dealers said.
PBLOF 1295 BSMAF 5025 HIPEF 1818 5199
KUALA LUMPUR, March 12 — Shares on Bursa Malaysia remained higher at mid-morning today as traders took advantage of positive and encouraging micro and macro-economic environment, as it propelled buying momentum among traders.
PBLOF 1295 BSMAF 5025 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...